|Brian Pereira left the CEO’s job last month after Amag shareholders voted down the acquisition of Allos Therapeutics Inc.|
Amag cleared to sell drug in Canada
Amag Pharmaceuticals Inc. said Monday its iron deficiency treatment Feraheme received regulatory approval in Canada, and the company will get a $3 million milestone payment when commercial sales start there. Japanese drugmaker Takeda Pharmaceutical Co. Ltd. has an exclusive license to sell the drug in Canada. Feraheme treats iron deficiency anemia in adults with chronic kidney disease, and it has been available in the United States for more than two years. Amag, based in Lexington, Mass., also is seeking approval to sell the drug in Europe.